MARKET

ALT

ALT

Altimmune
NASDAQ
7.26
+0.06
+0.83%
Pre Market: 7.15 -0.11 -1.52% 04:01 04/29 EDT
OPEN
7.18
PREV CLOSE
7.20
HIGH
7.42
LOW
6.90
VOLUME
293
TURNOVER
0
52 WEEK HIGH
14.84
52 WEEK LOW
2.090
MARKET CAP
514.70M
P/E (TTM)
-4.3706
1D
5D
1M
3M
1Y
5Y
Roche: Value Remains Despite Covid-19 Revenue Growth Loss
Roche has good long-term prospects despite Covid-19 revenue growth loss. Vabysmo and Phesgo are still strong growth drivers for the company going forward. Ocrevus is expected to remain as the best-selling Multiple Sclerosis Drug in 2030. The company has established a huge acquisition for drugs for the obesity drugs market.
Seeking Alpha · 23h ago
ALT January 2026 Options Begin Trading
NASDAQ · 2d ago
Altimmune Statement on the Passing of Dr. Stephen Harrison
Barchart · 3d ago
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 5d ago
Weekly Report: what happened at ALT last week (0415-0419)?
Weekly Report · 6d ago
13 new obesity drugs could hit the market by 2029 amid surging demand
13 new obesity drugs could hit the market by 2029 amid surging demand for the products in the U.S. World Health Organization predicts 50% of US adults will be considered obese by 2030. Sales of weight-loss drugs have soared, with Novo Nordisk and Eli Lilly generating $9.7B in 2023.
Seeking Alpha · 04/22 00:04
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
Recent trial data from Viking Therapeutics could make it a potential acquisition target for Pfizer. The GLP-1 weight loss market is projected to grow to $100 billion by 2030. Novo Nordisk and Eli Lilly are the leaders in the space. Pfizer makes logical sense in a potential deal for Viking. The company recently completed a successful Phase 2 trial of its drug in the obesity treatment.
Seeking Alpha · 04/15 20:08
Weekly Report: what happened at ALT last week (0408-0412)?
Weekly Report · 04/15 10:37
More
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Webull offers Altimmune Inc stock information, including NASDAQ: ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.